Bristol-Myers Squibb falls 2.6% after positive Phase 3 topline trial results

What happened

Bristol-Myers Squibb (BMY) fell 2.6% on October 12, 2026, after it reported positive topline Phase 3 results for RYZ101 in GEP-NETs and for admilparant in idiopathic pulmonary fibrosis. The announcements, reported by Business Wire and Benzinga, came as coverage noted the stock had risen 35.7% year‑over‑year on pipeline progress. Trading was heavier than normal and the company-specific news was the likely driver of the move.

How big was the move

The stock closed at $57.58 and fell 2.6% on the day, a decline equal to 1.8 times a typical daily move for this stock. Trading volume was 1.7 times its 20-day average. The S&P 500 fell 0.1% on the day, while the Healthcare sector median fell 1.0%, leaving the stock 1.6 percentage points worse than the sector median.

Over the last five sessions the stock fell 2.1%. In the past five years the stock had 50 sessions with a decline of at least 2.6%; twenty trading days later the median result was a decline of 0.4%, and 23 of 50 were higher. Market sensitivity shows a beta of 0.22, meaning the stock tends to move less than the market, which reinforces that this was a largely company-specific session.

The technical picture

The stock was 6.4% below its 20-day moving average, 10.0% below its 50-day moving average and 3.3% below its 200-day moving average. The 50-day average is above the 200-day average, a sign of an established uptrend. The Relative Strength Index (14 days) read 29, below 30, a level often called oversold.

Over one month the stock fell 9.5% and over three months it rose 1.1%. Over one year the stock rose 28.9%, which is 13.0 percentage points ahead of the S&P 500. The stock sat 16.1% below the 52-week high. Volatility was 24% annualized over 60 days, lower than 53% of its own readings over five years.

Fundamentals and valuation

For the four quarters through June 30, 2026, revenue was $49.19 billion, which grew 3.1% from a year earlier. Diluted earnings per share were $4.54, up 83.4% from a year earlier. Gross margin was 70.2%, up from 65.2% a year earlier.

Operating margin was 28.3%, compared with 25.3% a year earlier. Free-cash-flow margin was 23.3% and return on invested capital was 15.4%. The balance sheet showed net debt of 2.1 times EBITDA, and share count over one year increased by 0.5%.

The stock trades at 12.7 times trailing earnings and 8.3 times expected earnings, with a free-cash-flow yield of 9.5%. Versus its own history the price to trailing earnings is lower than 93% of its own readings over the past five years; the five-year median is 17.5 times earnings. PromtFinance scores rank the company high on Value at 96 (Exceptional) and Stability at 95 (Exceptional), with Quality at 83 (Strong) and Growth at 42 (Weak).

Earnings and analyst expectations

The next report is scheduled for October 29, 2026. The last report, on July 30, 2026, showed earnings per share of $2.04 against $1.60 expected, 27.5% above estimates. The company had a streak of 12 consecutive quarters beating estimates and an average surprise over the last four reports of 12.1% above estimates.

Typical two-day reactions after recent reports saw the stock rose 1.9%. Analysts number 42 with a consensus price target of $65.18, which is 13.2% above the closing price, and the consensus rating is Hold. Forty-five percent of analysts with a rating rate the stock Buy.

What to watch

• October 29, 2026: next quarterly earnings report date.
• Recent news: Phase 3 topline results for RYZ101 in GEP-NETs and Phase 3 ALOFT‑IPF trial of admilparant met primary endpoints, reported by Business Wire and Benzinga.
• Trading metrics: trading volume was 1.7 times its 20-day average and the move was 1.8 times a typical daily move for this stock.
• Valuation context: price to trailing earnings is 12.7 times trailing earnings and lower than 93% of its own readings over the past five years.